Fast Five Quiz: Severe Asthma Management

Praveen Buddiga, MD


July 07, 2021

The management of severe asthma during the COVID-19 pandemic has been challenging and may continue to be for some time. While evidence about COVID-19 is rapidly evolving, available data suggest that biologics for severe asthma do not seem to increase the risk for infection and severe COVID-19.

According to a recent systematic review and meta-analysis about asthma and COVID-19, the prevalence of asthma among patients with COVID-19 is similar to the global prevalence of asthma. The overall findings indicate that people with asthma may in fact have a lower risk than those without asthma for acquiring COVID-19 infection and have similar clinical outcomes.

Emerging data suggest that inhaled corticosteroids may be associated with a protective effect against severe COVID-19 infection. One recent study found that use of inhaled corticosteroids was lower in patients who required hospitalization due to COVID-19, as compared with nonhospitalized patients. Similarly, although asthmatic patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat level, COVID-19–related hospitalizations in these patients were comparatively low.

Learn more about COVID-19 infection and asthma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.